Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Reply to Frange and Leruez-Ville, "Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases".

Turner NA, Wolfe CR.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00453-19. doi: 10.1128/AAC.00453-19. Print 2019 May. No abstract available.

PMID:
31023820
2.

Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.

Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, Holland TL, Fowler VG Jr.

Nat Rev Microbiol. 2019 Apr;17(4):203-218. doi: 10.1038/s41579-018-0147-4. Review.

PMID:
30737488
3.

Strength in Numbers: Cardiac Fibroblast Clustering and Myocardial Remodeling.

Turner NA.

Circ Res. 2018 Jun 22;123(1):12-14. doi: 10.1161/CIRCRESAHA.118.313280. No abstract available.

4.

Expression and function of TLR4- induced B1R bradykinin receptor on cardiac fibroblasts.

Muñoz-Rodríguez C, Fernández S, Osorio JM, Olivares F, Anfossi R, Bolivar S, Humeres C, Boza P, Vivar R, Pardo-Jimenez V, Hemmings KE, Turner NA, Díaz-Araya G.

Toxicol Appl Pharmacol. 2018 Jul 15;351:46-56. doi: 10.1016/j.taap.2018.05.011. Epub 2018 May 26.

5.

MicroRNA-21 drives the switch to a synthetic phenotype in human saphenous vein smooth muscle cells.

Alshanwani AR, Riches-Suman K, O'Regan DJ, Wood IC, Turner NA, Porter KE.

IUBMB Life. 2018 Jul;70(7):649-657. doi: 10.1002/iub.1751. Epub 2018 Apr 16.

6.

Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism.

Bageghni SA, Hemmings KE, Zava N, Denton CP, Porter KE, Ainscough JFX, Drinkhill MJ, Turner NA.

FASEB J. 2018 Sep;32(9):4941-4954. doi: 10.1096/fj.201701455RR. Epub 2018 Mar 30.

7.

Influence of Reported Penicillin Allergy on Mortality in MSSA Bacteremia.

Turner NA, Moehring R, Sarubbi C, Wrenn RH, Drew RH, Cunningham CK, Fowler VG, Anderson DJ.

Open Forum Infect Dis. 2018 Feb 19;5(3):ofy042. doi: 10.1093/ofid/ofy042. eCollection 2018 Mar.

8.

Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Sartain SE, Turner NA, Moake JL.

J Biol Chem. 2018 May 11;293(19):7195-7208. doi: 10.1074/jbc.RA118.002639. Epub 2018 Mar 19.

9.

11β-HSD1 suppresses cardiac fibroblast CXCL2, CXCL5 and neutrophil recruitment to the heart post MI.

Mylonas KJ, Turner NA, Bageghni SA, Kenyon CJ, White CI, McGregor K, Kimmitt RA, Sulston R, Kelly V, Walker BR, Porter KE, Chapman KE, Gray GA.

J Endocrinol. 2017 Jun;233(3):315-327. doi: 10.1530/JOE-16-0501.

10.

Mapping the methylation status of the miR-145 promoter in saphenous vein smooth muscle cells from individuals with type 2 diabetes.

Riches K, Huntriss J, Keeble C, Wood IC, O'Regan DJ, Turner NA, Porter KE.

Diab Vasc Dis Res. 2017 Mar;14(2):122-129. doi: 10.1177/1479164116677968. Epub 2016 Dec 21.

11.

Tenascin C upregulates interleukin-6 expression in human cardiac myofibroblasts via toll-like receptor 4.

Maqbool A, Spary EJ, Manfield IW, Ruhmann M, Zuliani-Alvarez L, Gamboa-Esteves FO, Porter KE, Drinkhill MJ, Midwood KS, Turner NA.

World J Cardiol. 2016 May 26;8(5):340-50. doi: 10.4330/wjc.v8.i5.340.

12.

TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells.

Sartain SE, Turner NA, Moake JL.

J Immunol. 2016 Jan 15;196(2):832-45. doi: 10.4049/jimmunol.1500960. Epub 2015 Dec 16.

13.

Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs).

Turner NA.

J Mol Cell Cardiol. 2016 May;94:189-200. doi: 10.1016/j.yjmcc.2015.11.002. Epub 2015 Nov 2. Review.

14.

Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings.

Turner NA, Moake JL.

PLoS One. 2015 Oct 16;10(10):e0140740. doi: 10.1371/journal.pone.0140740. eCollection 2015.

16.

IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism.

Alase AA, El-Sherbiny YM, Vital EM, Tobin DJ, Turner NA, Wittmann M.

J Invest Dermatol. 2015 Dec;135(12):2935-2943. doi: 10.1038/jid.2015.317. Epub 2015 Aug 19.

17.

A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte-specific activity of angiotensin II type-1 receptor in mice.

Frentzou GA, Drinkhill MJ, Turner NA, Ball SG, Ainscough JF.

Dis Model Mech. 2015 Aug 1;8(8):783-94. doi: 10.1242/dmm.019174. Epub 2015 Jun 18.

18.

Aberrant phenotype in human endothelial cells of diabetic origin: implications for saphenous vein graft failure?

Roberts AC, Gohil J, Hudson L, Connolly K, Warburton P, Suman R, O'Toole P, O'Regan DJ, Turner NA, Riches K, Porter KE.

J Diabetes Res. 2015;2015:409432. doi: 10.1155/2015/409432. Epub 2015 Apr 8.

19.

Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H and factor I, are not packaged in Weibel-Palade bodies.

Turner NA, Sartain SE, Hui SK, Moake JL.

PLoS One. 2015 Mar 24;10(3):e0121994. doi: 10.1371/journal.pone.0121994. eCollection 2015.

20.

Exposure to inflammatory cytokines selectively limits GM-CSF production by induced T regulatory cells.

Reynolds BC, Turner DG, McPherson RC, Prendergast CT, Phelps RG, Turner NA, O'Connor RA, Anderton SM.

Eur J Immunol. 2014 Nov;44(11):3342-52. doi: 10.1002/eji.201444687. Epub 2014 Oct 1.

21.

Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function.

Riches K, Alshanwani AR, Warburton P, O'Regan DJ, Ball SG, Wood IC, Turner NA, Porter KE.

J Mol Cell Cardiol. 2014 Sep;74:240-50. doi: 10.1016/j.yjmcc.2014.05.018. Epub 2014 Jun 10.

22.

Investigating inherent functional differences between human cardiac fibroblasts cultured from nondiabetic and Type 2 diabetic donors.

Sedgwick B, Riches K, Bageghni SA, O'Regan DJ, Porter KE, Turner NA.

Cardiovasc Pathol. 2014 Jul-Aug;23(4):204-10. doi: 10.1016/j.carpath.2014.03.004. Epub 2014 Mar 26.

23.

Type 2 diabetes impairs venous, but not arterial smooth muscle cell function: possible role of differential RhoA activity.

Riches K, Warburton P, O'Regan DJ, Turner NA, Porter KE.

Cardiovasc Revasc Med. 2014 Apr;15(3):141-8. doi: 10.1016/j.carrev.2014.02.005. Epub 2014 Mar 2.

24.

Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor.

Lo NC, Turner NA, Cruz MA, Moake J.

J Biol Chem. 2013 Nov 15;288(46):33118-23. doi: 10.1074/jbc.M113.487413. Epub 2013 Oct 4.

25.

Effects of interleukin-1 on cardiac fibroblast function: relevance to post-myocardial infarction remodelling.

Turner NA.

Vascul Pharmacol. 2014 Jan;60(1):1-7. doi: 10.1016/j.vph.2013.06.002. Epub 2013 Jun 24. Review.

26.

Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms.

Riches K, Franklin L, Maqbool A, Peckham M, Adams M, Bond J, Warburton P, Feric NT, Koschinsky ML, O'Regan DJ, Ball SG, Turner NA, Porter KE.

Int J Biochem Cell Biol. 2013 Aug;45(8):1776-83. doi: 10.1016/j.biocel.2013.05.021. Epub 2013 May 31.

27.

Combined effects of interleukin-1α and transforming growth factor-β1 on modulation of human cardiac fibroblast function.

van Nieuwenhoven FA, Hemmings KE, Porter KE, Turner NA.

Matrix Biol. 2013 Oct-Nov;32(7-8):399-406. doi: 10.1016/j.matbio.2013.03.008. Epub 2013 Apr 12.

28.
29.

Mechanical activation of a multimeric adhesive protein through domain conformational change.

Wijeratne SS, Botello E, Yeh HC, Zhou Z, Bergeron AL, Frey EW, Patel JM, Nolasco L, Turner NA, Moake JL, Dong JF, Kiang CH.

Phys Rev Lett. 2013 Mar 8;110(10):108102. Epub 2013 Mar 5.

30.

Interleukin-1 has opposing effects on connective tissue growth factor and tenascin-C expression in human cardiac fibroblasts.

Maqbool A, Hemmings KE, O'Regan DJ, Ball SG, Porter KE, Turner NA.

Matrix Biol. 2013 Apr 24;32(3-4):208-14. doi: 10.1016/j.matbio.2013.02.003. Epub 2013 Feb 20.

31.

Function and fate of myofibroblasts after myocardial infarction.

Turner NA, Porter KE.

Fibrogenesis Tissue Repair. 2013 Mar 1;6(1):5. doi: 10.1186/1755-1536-6-5.

32.

p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts.

Sinfield JK, Das A, O'Regan DJ, Ball SG, Porter KE, Turner NA.

Biochem Biophys Res Commun. 2013 Jan 4;430(1):419-24. doi: 10.1016/j.bbrc.2012.11.071. Epub 2012 Dec 1.

33.

The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction.

van Nieuwenhoven FA, Turner NA.

Vascul Pharmacol. 2013 Mar;58(3):182-8. doi: 10.1016/j.vph.2012.07.003. Epub 2012 Aug 3. Review.

34.

WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

Liu Q, Chen H, Ojode T, Gao X, Anaya-O'Brien S, Turner NA, Ulrick J, DeCastro R, Kelly C, Cardones AR, Gold SH, Hwang EI, Wechsler DS, Malech HL, Murphy PM, McDermott DH.

Blood. 2012 Jul 5;120(1):181-9. doi: 10.1182/blood-2011-12-395608. Epub 2012 May 17.

35.

Divergent effects of 17-β-estradiol on human vascular smooth muscle and endothelial cell function diminishes TNF-α-induced neointima formation.

Nintasen R, Riches K, Mughal RS, Viriyavejakul P, Chaisri U, Maneerat Y, Turner NA, Porter KE.

Biochem Biophys Res Commun. 2012 Apr 20;420(4):828-33. doi: 10.1016/j.bbrc.2012.03.082. Epub 2012 Mar 23.

PMID:
22465119
36.

Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts.

Turner NA, Porter KE.

IUBMB Life. 2012 Feb;64(2):143-50. doi: 10.1002/iub.594. Epub 2012 Jan 3. Review.

37.

Therapeutic regulation of cardiac fibroblast function: targeting stress-activated protein kinase pathways.

Turner NA.

Future Cardiol. 2011 Sep;7(5):673-91. doi: 10.2217/fca.11.41. Review.

38.

Changes in glutamate transporter expression in mouse forebrain areas following focal ischemia.

Ketheeswaranathan P, Turner NA, Spary EJ, Batten TF, McColl BW, Saha S.

Brain Res. 2011 Oct 18;1418:93-103. doi: 10.1016/j.brainres.2011.08.029. Epub 2011 Aug 19.

PMID:
21911209
39.

Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation.

Turner NA, Das A, O'Regan DJ, Ball SG, Porter KE.

Int J Biochem Cell Biol. 2011 Oct;43(10):1450-8. doi: 10.1016/j.biocel.2011.06.008. Epub 2011 Jun 21.

PMID:
21718796
40.

Statins and myocardial remodelling: cell and molecular pathways.

Porter KE, Turner NA.

Expert Rev Mol Med. 2011 Jul 1;13:e22. doi: 10.1017/S1462399411001931. Review.

PMID:
21718586
41.

MMP-3 (5A/6A) polymorphism does not influence human smooth muscle cell invasion.

Maqbool A, Keswani A, Galloway S, O'Regan DJ, Ball SG, Turner NA, Porter KE.

J Surg Res. 2012 Jun 15;175(2):343-9. doi: 10.1016/j.jss.2011.03.043. Epub 2011 Apr 17.

PMID:
21601886
42.

Modulatory effect of interleukin-1α on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase.

Turner NA, Warburton P, O'Regan DJ, Ball SG, Porter KE.

Matrix Biol. 2010 Sep;29(7):613-20. doi: 10.1016/j.matbio.2010.06.007. Epub 2010 Jul 7.

43.

Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein.

Mughal RS, Scragg JL, Lister P, Warburton P, Riches K, O'Regan DJ, Ball SG, Turner NA, Porter KE.

Diabetologia. 2010 Aug;53(8):1761-71. doi: 10.1007/s00125-010-1736-6. Epub 2010 May 12.

44.

Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage.

Turner NA, Nolasco L, Ruggeri ZM, Moake JL.

Blood. 2009 Dec 3;114(24):5102-11. doi: 10.1182/blood-2009-07-231597. Epub 2009 Oct 12.

45.

Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients.

Madi HA, Riches K, Warburton P, O'Regan DJ, Turner NA, Porter KE.

Am J Physiol Cell Physiol. 2009 Nov;297(5):C1307-17. doi: 10.1152/ajpcell.00608.2008. Epub 2009 Sep 9.

46.

Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.

Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE.

Clin Exp Pharmacol Physiol. 2009 May;36(5-6):478-86. doi: 10.1111/j.1440-1681.2008.05088.x. Epub 2008 Oct 8.

PMID:
19673929
47.

Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts.

Turner NA, Das A, Warburton P, O'Regan DJ, Ball SG, Porter KE.

Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1117-27. doi: 10.1152/ajpheart.00372.2009. Epub 2009 Jul 31.

48.

The -1562C/T MMP-9 promoter polymorphism does not predict MMP-9 expression levels or invasive capacity in saphenous vein smooth muscle cells cultured from different patients.

Maqbool A, Turner NA, Galloway S, Riches K, O'Regan DJ, Porter KE.

Atherosclerosis. 2009 Dec;207(2):458-65. doi: 10.1016/j.atherosclerosis.2009.05.028. Epub 2009 Jun 6.

PMID:
19541314
49.

Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts.

Riches K, Morley ME, Turner NA, O'Regan DJ, Ball SG, Peers C, Porter KE.

J Mol Cell Cardiol. 2009 Sep;47(3):391-9. doi: 10.1016/j.yjmcc.2009.06.002. Epub 2009 Jun 11.

50.

Cardiac fibroblasts: at the heart of myocardial remodeling.

Porter KE, Turner NA.

Pharmacol Ther. 2009 Aug;123(2):255-78. doi: 10.1016/j.pharmthera.2009.05.002. Epub 2009 May 19. Review.

PMID:
19460403

Supplemental Content

Loading ...
Support Center